Oral Session

Oral Session 1-13B MPN: Clinical (1)

Fri. Oct 12, 2018 10:10 AM - 11:10 AM No.13 (Osaka International Convention Center, 11F 1101-2)

Chair: Junko Ohyashiki (Department of Adveanced Callular Therapy, Tokyo Medical University, Japan)

+Add all to schedule

[OS1-13B-1] JAK2 T875N, a causative novel activating germline mutation for familial essential thrombocytosis

Makoto Yoshimitsu¹, Miho Hachiman¹, Kotaro Shide², Kazuya Shimoda², Kenji Ishitsuka¹ (1.Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan, 2.Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan)

[OS1-13B-2] Clinical and molecular features of patients with triple-negative essential thrombocythemia

Tadaaki Inano¹, Marito Araki², Yasutaka Fukuda¹, Soji Morishita², Tomonori Ochiai¹, Kyohei Misawa¹, Masafumi Ito³, Kouji Yamamoto⁴, Yinjie Yang¹, Teppei Taguchi¹, Yoko Edahiro¹, Misa Imai¹, Akihiko Gotoh¹, Akimichi Ohsaka², Norio Komatsu¹ (1.Hematol, Juntendo Univ. Graduate School of Med., Tokyo, Japan, 2.Transfusion Med. & Stem Cell Regu, Juntendo Univ., Tokyo, Japan, 3.Pathol, Japanese Red Cross Nagoya Daiichi Hosp., Aichi, Japan, 4.Medical Statistics, Osaka City Univ., Osaka, Japan)

[OS1-13B-3] TET2 mutation is a poor prognostic factor for survival in BCR-ABL-negative MPN patients

Yasuhiro Taniguchi¹, Hirokazu Tanaka¹, Ryosuke Fujiwara¹, Yasuyoshi Morita¹, Hitoshi Hanamoto², Yoichi Tatsumi¹, Takashi Ashida¹, Itaru Matsumura¹ (1.Hematol. and Rheumatol., Kindai Univ, Osaka, Japan, 2.Kindai Univ. Nara Hospital, Nara, Japan)

[OS1-13B-4] Clinical effects of mutation subtypes and allele burden in CALR-mutant essential thrombocythemia

Masafumi Matsuguma, Toshiaki Yujiri, Yasuko Kajimura, Yoshihiro Tokunaga, Kaoru Yamamoto, Akiko Sugiyama, Mayumi Tanaka, Yoshinori Tanaka, Yukinori Nakamura, Yukio Tanizawa (3rd Dept. Int. Med., Yamaguchi Univ., Yamaguchi, Japan)

[OS1-13B-5] Microarray-based simultaneous analysis kit for MPN driver mutations in the JAK2, MPL and CALR genes

Emi Takamitsu¹, Mitsuyoshi Ohba¹, Hirofumi Yamano¹, Masafumi Matsuguma², Toshiaki Yujiri² (1.Life science Technology Group, Toyo Kohan Co., Ltd., Yamaguchi, Japan, 2.3rd Department of Internal Medicine, Yamaguchi University Hospital, Yamaguchi, Japan)

[OS1-13B-6] Analysis of JAK2, CALR and MPL mutational status in myeloproliferative neoplasms

Masahiro Takeuchi¹, Takaaki Tanami¹, Yasuhito Hatanaka¹, Jun Takiguchi¹, Arata Ishii¹, Yurie Nagai¹, Tatsuzo Mishina¹, Yusuke Isshiki¹, Kensuke Kayamori¹, Kenji Kimura¹, Koji Takaishi¹, Yutaro Hino¹, Nagisa Oshima¹, Shokichi Tsukamoto¹, Shio Mitsukawa^1,4, Yusuke Takeda¹, Naoya Mimura^1,4, Chikako Ohwada¹, Tohru Iseki^1,4, Yuriko Tsukamoto³, Hiroyuki Ebinuma³, Chiaki Nakaseko^1,2, Emiko Sakaida¹ (1.Department of Hematology, Chiba University Hospital, 2.Department of Hematology, International University of Health and Welfare, 3.Sekisui Medical Co,. Ltd., 4.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital)